Clinical, humanistic, and economic burden of chronic obstructive pulmonary disease (COPD) in Canada: a systematic review

BMC Research Notes

Mark Bernauer²  Victoria Zarotsky²  Shiyuan Zhang³  Afisi Ismaila¹  Tam Dang-Tan³ 

[1] Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada;Optum, Eden Prairie, MN, USA;GlaxoSmithKline, 7333 Mississauga Road, Mississauga L5N 6L4, ON, Canada

关键词: Quality of life;    Humanistic;    Economic;    Clinical;    Costs;    Canada;    Burden of illness;    Burden;    Literature review;    Chronic obstructive;    COPD;   

Others  :  1230097
DOI  :  10.1186/s13104-015-1427-y

 received in 2014-07-31, accepted in 2015-09-09,  发布年份 2015

【 摘 要 】

Background

Chronic obstructive pulmonary disease (COPD) is a chronic, irreversible disease and a leading cause of worldwide morbidity and mortality. In Canada, COPD is the fourth leading cause of death. This systematic review was undertaken to update healthcare professionals and decision makers regarding the recent clinical, humanistic and economic burden evidence in Canada.

Methods

A systematic literature search was conducted in PubMed, EMBASE, and Cochrane databases to identify original research published January 2000 through December 2012 on the burden of COPD in Canada. Each search was conducted using controlled vocabulary and key words, with “COPD” as the main search concept and limited to Canadian studies, written in English and involving human subjects. Selected studies included randomized controlled trials, observational studies and systematic reviews/meta-analyses that reported healthcare resource utilization, quality of life and/or healthcare costs.

Results

Of the 972 articles identified through the literature searches, 70 studies were included in this review. These studies were determined to have an overall good quality based on the quality assessment. COPD patients were found to average 0–4 annual emergency department visits, 0.3–1.5 annual hospital visits, and 0.7–5 annual physician visits. Self-care management was found to lessen the overall risk of emergency department (ED) visits, hospitalization and unscheduled physician visits. Additionally, integrated care decreased the mean number of hospitalizations and telephone support reduced the number of annual physician visits. Overall, 60–68 % of COPD patients were found to be inactive and 60–72 % reported activity restriction. Pain was found to negatively correlate with physical activity while breathing difficulties resulted in an inability to leave home and reduced the ability to handle activities of daily living. Evidence indicated that treating COPD improved patients’ overall quality of life. The average total cost per patient ranged between CAN $2444–4391 from a patient perspective to CAN $3910–6693 from a societal perspective. Furthermore, evidence indicated that COPD exacerbations lead to higher costs.

Conclusions

The clinical, humanistic and economic burden of COPD in Canada is substantial. Use of self-care management programs, telephone support, and integrated care may reduce the overall burden to Canadian patients and society.

【 授权许可】

   
2015 Dang-Tan et al.

【 图 表 】

Fig.1.

Fig.2.

【 参考文献 】

• [1]Chapman KR, Bourbeau J, Rance L: The burden of COPD in Canada: results from the Confronting COPD survey. Respir Med 2003, 97(Suppl C):S23-S31.
• [2]Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, et al.: Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006, 27:397-412.
• [3]Mittmann N, Kuramoto L, Seung SJ, Haddon JM, Bradley-Kennedy C, FitzGerald JM: The cost of moderate and severe COPD exacerbations to the Canadian healthcare system. Respir Med 2008, 102:413-421.
• [4]GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2013. http://www.goldcopd.org. Accessed 1 Aug 2011.
• [5]Gershon AS, Wang C, Wilton AS, Raut R, To T: Trends in chronic obstructive pulmonary disease prevalence, incidence, and mortality in ontario, Canada, 1996–2007: a population-based study. Arch Intern Med 2010, 170:560-565.
• [6]Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al.: International variation in the prevalence of COPD (the BOLD study): a population-based prevalence study. Lancet 2007, 370:741-750.
• [7]Celli BR, Halbert RJ, Nordyke RJ, Schau B: Airway obstruction in never smokers: results from the Third National Health and Nutrition Examination Survey. Am J Med 2005, 118:1364-1372.
• [8]Behrendt CE: Mild and moderate-to-severe COPD in nonsmokers: distinct demographic profiles. Chest 2005, 128:1239-1244.
• [9]Bridevaux PO, Probst-Hensch NM, Schindler C, Curjuric I, Felber DD, Braendli O, et al.: Prevalence of airflow obstruction in smokers and never-smokers in Switzerland. Eur Respir J 2010, 36:1259-1269.
• [10]Mannino DM, Watt G, Hole D, Gillis C, Hart C, McConnachie A, et al.: The natural history of chronic obstructive pulmonary disease. Eur Respir J 2006, 27:627-643.
• [11]Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE: The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005, 142:233-239.
• [12]McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA: Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007, 62:411-415.
• [13]National Institute for Health and Clinical Excellence. The guidelines manual (January 2009). 2009. London: National Institute for Health and Clinical Excellence. http://www.nice.org.uk. Accessed 17 March 2011.
• [14]National Institute for Health and Clinical Excellence. The guidelines manual (January 2009). 2009. London: National Instutute for Health and Clinical Excellence. http://www.nice.org.uk. Accessed 17 March 2011.
• [15]Moher R, Liberati A, Tetzlaff J, Altman D: The PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6(7):e10000097.
• [16]Gaebel K, McIvor RA, Xie F, Blackhouse G, Robertson D, Assasi N, et al.: Triple therapy for the management of COPD: a review. COPD 2011, 8:206-243.
• [17]Polisena J, Tran K, Cimon K, Hutton B, McGill S, Palmer K, et al.: Home telehealth for chronic obstructive pulmonary disease: a systematic review and meta-analysis. J Telemed Telecare 2010, 16:120-127.
• [18]Quon BS, Gan WQ, Sin DD: Contemporary management of acute exacerbations of COPD: a systematic review and metaanalysis. Chest 2008, 133:756-766.
• [19]Keenan SP, Gregor J, Sibbald WJ, Cook D, Gafni A: Noninvasive positive pressure ventilation in the setting of severe, acute exacerbations of chronic obstructive pulmonary disease: more effective and less expensive. Crit Care Med 2000, 28:2094-2102.
• [20]Chan CK, Maltais F, Sigouin C, Haddon JM, Ford GT: A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Can Respir J 2007, 14:465-472.
• [21]Sedeno MF, Nault D, Hamd DH, Bourbeau J: A self-management education program including an action plan for acute COPD exacerbations. COPD 2009, 6:352-358.
• [22]Moullec G, Favreau H, Lavoie KL, Labrecque M: Does a self-management education program have the same impact on emotional and functional dimensions of HRQoL? COPD 2012, 9:36-45.
• [23]Vozoris NT, O’Donnell DE: Prevalence, risk factors, activity limitation and health care utilization of an obese, population-based sample with chronic obstructive pulmonary disease. Can Respir J 2012, 19:e18-e24.
• [24]Leigh R, Pizzichini MM, Morris MM, Maltais F, Hargreave FE, Pizzichini E: Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 2006, 27:964-971.
• [25]HajGhanbari B, Holsti L, Road JD, Darlene RW: Pain in people with chronic obstructive pulmonary disease (COPD). Respir Med 2012, 106:998-1005.
• [26]Rocker G, Young J, Donahue M, Farquhar M, Simpson C: Perspectives of patients, family caregivers and physicians about the use of opioids for refractory dyspnea in advanced chronic obstructive pulmonary disease. CMAJ 2012, 184:E497-E504.
• [27]Low G, Gutman G: Couples’ ratings of chronic obstructive pulmonary disease patients’ quality of life. Clin Nurs Res 2003, 12:28-48.
• [28]Moullec G, Lavoie KL, Rabhi K, Julien M, Favreau H, Labrecque M: Effect of an integrated care programme on re-hospitalization of patients with chronic obstructive pulmonary disease. Respirology 2012, 17:707-714.
• [29]Labrecque M, Rabhi K, Laurin C, Favreau H, Moullec G, Lavoie K, et al.: Can a self-management education program for patients with chronic obstructive pulmonary disease improve quality of life? Can Respir J 2011, 18:e77-e81.
• [30]Rowe BH, Voaklander DC, Marrie TJ, Senthilselvan A, Klassen TP, Rosychuk RJ: Outcomes following chronic obstructive pulmonary disease presentations to emergency departments in Alberta: a population-based study. Can Respir J 2010, 17:295-300.
• [31]Rosychuk RJ, Voaklander DC, Senthilselvan A, Klassen TP, Marrie TJ, Rowe BH: Presentations to emergency departments for chronic obstructive pulmonary disease in Alberta: a population-based study. CJEM 2010, 12:500-508.
• [32]Johnston NW, McIvor A, Lambert K, Greene JM, Hussack P, erhardsson DV, et al.: The Christmas season as a risk factor for chronic obstructive pulmonary disease exacerbations. Can Respir J 2010, 17:275-281.
• [33]Tsai CL, Rowe BH, Cydulka RK, Camargo CA Jr: ED visit volume and quality of care in acute exacerbations of chronic obstructive pulmonary disease. Am J Emerg Med 2009, 27:1040-1049.
• [34]Rowe BH, Cydulka RK, Tsai CL, Clark S, Sinclair D, Camargo CA Jr: Comparison of Canadian versus United States emergency department visits for chronic obstructive pulmonary disease exacerbation. Can Respir J 2008, 15:295-301.
• [35]Wang Q, Bourbeau J: Outcomes and health-related quality of life following hospitalization for an acute exacerbation of COPD. Respirology 2005, 10:334-340.
• [36]Golmohammadi K, Jacobs P, Sin DD: Economic evaluation of a community-based pulmonary rehabilitation program for chronic obstructive pulmonary disease. Lung 2004, 182:187-196.
• [37]Wouters EF: Economic analysis of the Confronting COPD survey: an overview of results. Respir Med. 2003, 97(Suppl C):S3-S14.
• [38]Sin DD, Tu JV: Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164:580-584.
• [39]Bischoff EW, Hamd DH, Sedeno M, Benedetti A, Schermer TR, Bernard S, et al.: Effects of written action plan adherence on COPD exacerbation recovery. Thorax 2011, 66:26-31.
• [40]Stephenson A, Seitz DP, Fischer HD, Gruneir A, Bell CM, Gershon AS, et al.: Cholinesterase inhibitors and adverse pulmonary events in older people with chronic obstructive pulmonary disease and concomitant dementia: a population-based, cohort study. Drugs Aging 2012, 29:213-223.
• [41]Blais L, Forget A, Ramachandran S: Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence. Clin Ther 2010, 32:1320-1328.
• [42]Gershon A, Croxford R, To T, Stanbrook MB, Upshur R, Sanchez-Romeu P, et al.: Comparison of inhaled long-acting beta-agonist and anticholinergic effectiveness in older patients with chronic obstructive pulmonary disease: a cohort study. Ann Intern Med 2011, 154:583-592.
• [43]FitzGerald JM, Haddon JM, Bradly-Kennedy C, Kuramoto L, Ford GT: Resource use study in COPD (RUSIC): a prospective study to quantify the effects of COPD exacerbations on health care resource use among COPD patients. Can Respir J 2007, 14:145-152.
• [44]Bourbeau J, Julien M, Maltais F, Rouleau M, Beaupré A, Bégin R, et al.: Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med 2003, 163:585-591.
• [45]Tsai CL, Camargo CA Jr: The role of body mass index in acute exacerbations of chronic obstructive pulmonary disease. Emerg Med J 2009, 26:701-705.
• [46]Ohinmaa A, Schopflocher D, Jacobs P, Demeter S, Chuck A, Golmohammadi K, et al.: A population-based analysis of health behaviours, chronic diseases and associated costs. Chronic Dis Can 2006, 27:17-24.
• [47]Wong AW, Gan WQ, Burns J, Sin DD, van Eeden SF: Acute exacerbation of chronic obstructive pulmonary disease: influence of social factors in determining length of hospital stay and readmission rates. Can Respir J 2008, 15:361-364.
• [48]Beaulieu-Genest L, Chretien D, Maltais F, Pelletier K, Parent JG, Lacasse Y: Self-administered prescriptions of oral steroids and antibiotics in chronic obstructive pulmonary disease: are we doing more harm than good? Chron Respir Dis 2007, 4:143-147.
• [49]Sin DD, Tu JV: Are elderly patients with obstructive airway disease being prematurely discharged? Am J Respir Crit Care Med 2000, 161:1513-1517.
• [50]Chen Y, Li Q, Johansen H: Age and sex variations in hospital readmissions for COPD associated with overall and cardiac comorbidity. Int J Tuberc Lung Dis 2009, 13:394-399.
• [51]Huiart L, Ernst P, Suissa S: Cardiovascular morbidity and mortality in COPD. Chest 2005, 128:2640-2646.
• [52]Goodridge D, Lawson J, Duggleby W, Marciniuk D, Rennie D, Stang M: Health care utilization of patients with chronic obstructive pulmonary disease and lung cancer in the last 12 months of life. Respir Med 2008, 102:885-891.
• [53]Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM: Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006, 47:2554-2560.
• [54]Appleton S, Poole P, Smith B, Veale A, Lasserson TJ, Chan-Matthew MK, et al.: Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006, 19(3):CD001104.
• [55]Lacasse Y, Beaudoin L, Rousseau L, Maltais F: Randomized trial of paroxetine in end-stage COPD. Monaldi Arch Chest Dis 2004, 61:140-147.
• [56]Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, et al.: Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Inter Med 2007, 146:545-555.
• [57]Bourbeau J, Rouleau MY, Boucher S: Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax 1998, 53:477-482.
• [58]Aaron SD, Vandemheen KL, Hebert P, Dales R, Stiell IG, Ahuja J, et al.: Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003, 348:2618-2625.
• [59]Maleki-Yazdi MR, Kelly SM, Lam SY, Marin M, Barbeau M, Walker V: The burden of illness in patients with moderate to severe chronic obstructive pulmonary disease in Canada. Can Respir J 2012, 19:319-324.
• [60]Dormuth CR, Morrow RL, Carney G: Trends in health care utilization in British Columbia following public coverage for tiotropium. Value Health 2011, 14:600-606.
• [61]Fletcher MJ, Upton J, Taylor-Fishwick J, Buist SA, Jenkins C, Hutton J, et al.: COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population. BMC Public Health 2011, 11:612. BioMed Central Full Text
• [62]Siddique HH, Olson RH, Parenti CM, Rector TS, Caldwell M, Dewan NA, et al.: Randomized trial of pragmatic education for low-risk COPD patients: impact on hospitalizations and emergency department visits. Int J Chron Obstruct Pulmon Dis 2012, 7:719-728.
• [63]Jackson BE, Suzuki S, Lo K, Su F, Singh KP, Coultas D, et al.: Geographic disparity in COPD hospitalization rates among the Texas population. Respir Med 2011, 105:734-739.
• [64]Aschan-Leygonie C, Baudet-Michel S, Mathian H, Sanders L: Gaining a better understanding of respiratory health inequalities among cities: an ecological case study on elderly males in the larger French cities. Int J Health Geogr 2013, 12:19. BioMed Central Full Text
• [65]Brown DW, Croft JB, Greenlund KJ, Giles WH: Trends in hospitalization with chronic obstructive pulmonary disease-United States, 1990–2005. COPD 2010, 7:59-62.
• [66]Jones PW, Brusselle G, Dal Negro RW, Ferrer M, Kardos P, Levy ML, et al.: Health-related quality of life in patients by COPD severity within primary care in Europe. Respir Med 2011, 105:57-66.
• [67]Blinderman CD, Homel P, Billings JA, Tennstedt S, Portenoy RK: Symptom distress and quality of life in patients with advanced chronic obstructive pulmonary disease. J Pain Symptom Manag 2009, 38:115-123.
• [68]Lohne V, Heer HC, Andersen M, Miaskowski C, Kongerud J, Rustoen T: Qualitative study of pain of patients with chronic obstructive pulmonary disease. Heart Lung 2010, 39:226-234.
• [69]Bentsen SB, Rustoen T, Miaskowski C: Prevalence and characteristics of pain in patients with chronic obstructive pulmonary disease compared to the Norwegian general population. J Pain 2011, 12:539-545.
• [70]Boros PW, Lubinski W: Health state and the quality of life in patients with chronic obstructive pulmonary disease in Poland: a study using the EuroQoL-5D questionnaire. Pol Arch Med Wewn 2012, 122:73-81.
• [71]Elkington H, White P, Addington-Hall J, Higgs R, Edmonds P: The healthcare needs of chronic obstructive pulmonary disease patients in the last year of life. Palliat Med 2005, 19:485-491.
• [72]Skilbeck J, Mott L, Page H, Smith D, Hjelmeland-Ahmedzai S, Clark D: Palliative care in chronic obstructive airways disease: a needs assessment. Palliat Med 1998, 12:245-254.
• [73]Chapman K, Kaplan A. Report: breaking the surface–breaking the silence: how the under-reporting of “Lung Attacks” in Canada impacts patient outcomes in COPD. 2012. http://copdcanada.info/resources/Breaking+the+Surface+-+Breaking+the+Silence+2012.pdf. Accessed 6 June 2013.
• [74]Eisenberg MJ, Atallah R, Grandi SM, Windle SB, Berry EM: Legislative approaches to tackling the obesity epidemic. CMAJ 2011, 183:1496-1500.
• [75]Gotay CC, Katzmarzyk PT, Janssen I, Dawson MY, Aminoltejari K, Bartley NL: Updating the canadian obesity maps: an epidemic in progress. Can J Public Health 2013, 104:e64-e68.
• [76]Chen Y, Stewart P, Dales R, Johansen H, Bryan S, Taylor G: Changing age-pattern of hospitalisation risk of chronic obstructive pulmonary disease in men and women in Canada. Age Ageing 2005, 34:373-377.
• [77]Beauchesne MF, Julien M, Julien LA, Piquette D, Forget A, Labrecque M, et al.: Antibiotics used in the ambulatory management of acute COPD exacerbations. Int J Chron Obstruct Pulmon Dis 2008, 3:319-322.
• [78]Tu AW, Buxton JA, Stockwell T: Estimates of smoking-attributable mortality and hospitalization in BC, 2002–2007. Can J Public Health 2012, 103:137-141.
• [79]Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring E Jr, et al.: Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006, 16:63-70.
• [80]Gonzalez AV, Suissa S, Ernst P: Gender differences in survival following hospitalisation for COPD. Thorax 2011, 66:38-42.
• [81]Macie C, Wooldrage K, Manfreda J, Anthonisen NR: Introduction of leukotriene receptor antagonists in Manitoba. Can Respir J 2006, 13:94-98.
• [82]Ernst P, Suissa S: Pneumonia in elderly patients with chronic obstructive pulmonary disease. Curr Infect Dis Rep 2008, 10:223-228.
• [83]Monfared AA, Lelorier J: Accuracy and validity of using medical claims data to identify episodes of hospitalizations in patients with COPD. Pharmacoepidemiol Drug Saf 2006, 15:19-29.
• [84]Benayoun S, Ernst P, Suissa S: The impact of combined inhaled bronchodilator therapy in the treatment of COPD. Chest 2001, 119:85-92.
• [85]Bourbeau J, Ernst P, Cockcoft D, Suissa S: Inhaled corticosteroids and hospitalisation due to exacerbation of COPD. Eur Respir J 2003, 22:286-289.
• [86]Disano J, Goulet J, Muhajarine N, Neudorf C, Harvey J: Social-economic status and rates of hospital admission for chronic disease in urban Canada. Can Nurse 2010, 106:24-29.
• [87]Keenan SP, Powers CE, McCormack DG: Noninvasive positive-pressure ventilation in patients with milder chronic obstructive pulmonary disease exacerbations: a randomized controlled trial. Respir Care 2005, 50:610-616.
• [88]Dormuth CR, Maclure M, Glynn RJ, Neumann P, Brookhart AM, Schneeweiss S: Emergency hospital admissions after income-based deductibles and prescription copayments in older users of inhaled medications. Clin Ther 2008, 30(Spec No):1038-1050.
• [89]Sin DD, Wells H, Svenson LW, Man SF: Asthma and COPD among aboriginals in Alberta, Canada. Chest 2002, 121:1841-1846.
• [90]Moineddin R, Nie JX, Domb G, Leong AM, Upshur RE: Seasonality of primary care utilization for respiratory diseases in Ontario: a time-series analysis. BMC Health Serv Res 2008, 8:160. BioMed Central Full Text